Engineered peptides targeting the LHX1-LDB1 complex

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Animals1

Outcomes

Head and neck squamous cell carcinoma

downin mice1

1 study

Engineered peptides targeting the LHX1-LDB1 complex decreases head and neck squamous cell carcinoma in mice.
“Therapeutic disruption of the LHX1-LDB1 complex using engineered peptides re-activated STING signaling, induced SASP, and significantly suppressed tumor growth.”
Animalsxenograft models
Targeting the LHX1-LDB1 Complex Restores STING-dependent Senescence Surveillance and Inhibits Head and Neck Cancer Progression
International journal of biological sciences1 Jan 2026

More on Head and neck squamous cell carcinoma

Latest

1 in 12 months

International Journal of Biological Sciences29 Jan

Targeting the LHX1-LDB1 Complex Restores STING-dependent Senescence Surveillance and Inhibits Head and Neck Cancer Progression

Experiments in miceHead and neck cancer

Paper

Engineered peptides targeting the LHX1-LDB1 complex

Outcomes

Latest

Targeting the LHX1-LDB1 Complex Restores STING-dependent Senescence Surveillance and Inhibits Head and Neck Cancer Progression

Related